ArticleEuropean thyroid journal2025
MAPK13 promotes the progression of papillary thyroid cancer.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Clinical and Functional Significance of p38δ (MAPK13) in Lung Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze the genes that influence PTC progression and investigate the role of MAPK13 in PTC. Methods: Differentially expressed genes (DEGs) in Gene Expression Omnibus (GEO): GSE3467, GSE3678, GSE33630, and GSE58545 were analyzed between PTC and normal thyroid tissues. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were performed on the DEGs using The Cancer Genome Atlas (TGCA) Program data. MAPK13 was subsequently identified as promoting progression in PTC. The association between MAPK13 expression and clinicopathological features was analyzed using data from public database and the collected cohort. The CCK-8 assay, EdU assay, wound healing assay, transwell assay, flow cytometry, GSEA enrichment analysis, and xenograft model were used to investigate the function of MAPK13 in PTC. Results: Higher expression of MAPK13 was associated with poorer progression-free survival, higher tumor pathologic stage, extrathyroidal extension, lymph node metastasis, multifocal tumors, American Thyroid Association (ATA) stratification system level, and BRAF V600E mutation. Overexpression of MAPK13 significantly promoted cell proliferation, migration, and invasion, and inhibited apoptosis of PTC. Knockdown of MAPK13 significantly inhibited cell proliferation, migration, and invasion, and promoted apoptosis of PTC. Epithelial-mesenchymal transition (EMT) was significantly enriched in GSEA analysis. Higher MAPK13 expression was related to higher N-cadherin and lower E-cadherin expression. Knockdown of MAPK13 significantly prevented tumor growth in vivo. Conclusion: MAPK13 promotes the malignant biological behavior of PTC cells and is associated with EMT. MAPK13 may be a potential biomarker for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.